Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Endotherapy for and tailored approaches to treating GERD, and refractory GERD
Locke, G. Richard, Horwhat, John D., Mashimo, Hiroshi , Savarino, Edoardo , Zentilin, Patrizia , Savarino, Vincenzo , Armbruster, Steven, Wong, Roy K.H., Moawad, Fouad J. , Zerbib, Frank , Savarino, Edoardo

Annals of the New York Academy of Sciences | June 6, 2014 | Volume: 1300 | Issue: 1 | Pages: 166-186

10.1111/nyas.12240 | PMID 24117641 Get It

This paper presents commentaries on how endoluminal antireflux procedures compare to laparoscopic fundoplication; new endoscopic procedures being studied to treat refractory gastroesophageal reflux disease (GERD); the new Stretta; the relationship between obesity and proton pump inhibitor (PPI) resistance; data concerning acid hypersensitivity and sensory receptors (vallinoid, TRPV1) causing refractory GERD; whether microscopic esophagitis is relevant in determining symptoms of non‐erosive reflux disease (NERD); how concomitant functional gastrointestinal disorders affect the PPI response in NERD; the evidence that a functional esophagus is associated with inflammatory bowel syndrome (IBS); the role of GABA agonists in the treatment of refractory GERD; the role of biofeedback and antidepressants in refractory GERD; and endoluminal fundoplication using the EsophyX device.
Causes, evaluation, and consequences of eosinophilic esophagitis
Chehade, Mirna , Achem, Sami R., Souza, Rhonda F. , Lucendo, Alfredo

Annals of the New York Academy of Sciences | June 6, 2014 | Volume: 1300 | Issue: 1 | Pages: 110-118

10.1111/nyas.12243 | PMID 24117638 Get It

This paper presents commentaries on whether eosinophilic esophagitis is a food allergy; inflammation in the context of eosinophilic esophagitis; whether eosinophilic esophagitis a cause of noncardiac chest pain; the role of endoscopy in the evaluation of eosinophilic esophagitis; and whether response to proton pump inhibitor therapy can distinguish eosinophilic esophagitis from gastroesophageal reflux disease.
Causes and treatments of achalasia, and primary disorders of the esophageal body
Félix, V. , DeVault, Kenneth R. , Penagini, Roberto , Elvevi, Alessandra, Swanström, Lee L. , Wassenaar, Eelco B., Crespin, Oscar M. , Pellegrini, Carlos A. , Wong, Roy K.H., DeVault, Kenneth, Penagini, Roberto

Annals of the New York Academy of Sciences | June 6, 2014 | Volume: 1300 | Issue: 1 | Pages: 236-249

10.1111/nyas.12254 | PMID 24117646 Get It

The following on achalasia and disorders of the esophageal body includes commentaries on controversies regarding whether patients with complete lower esophageal sphincter (LES) relaxation can be considered to exhibit early achalasia; the roles of different mucle components of the LES in achalasia; sensory neural pathways impaired in achalasia; indications for peroral endoscopic myotomy and advantages of the technique over laparoscopic and thorascopic myotomy; factors contributing to the success of surgical therapy for achalasia; modifications to the classification of esophageal body primary motility disorders in the advent of high‐resolution manometry (HRM); analysis of the LES in differentiating between achalasia and diffuse esophageal spasm (DES); and appropriate treatment for DES, nutcracker esophagus (NE), and hypertensive LES (HTLES).
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
Kumar, Shaji , Bensinger, William, Zimmerman, Todd M., Reeder, Craig B. , Berg, Deborah, Hui, Ai-Min, Gupta, Neeraj , Bacco, Alessandra Di , Jiang, Yu , Shou, Yaping, Niesvizky, Rubén, Berenson, James R. , Gupta, Neeraj

Blood | June 6, 2014 | Volume: 124 | Issue: 7 | Pages: 1047-1055

10.1182/blood-2014-01-548941 | PMID 24904120 Get It

Key Points Weekly oral proteasome inhibitor ixazomib appears generally well tolerated with manageable toxicity, limited grade 1/2 neuropathy. Data show that more than 25% of 30 evaluable relapsed/refractory myeloma patients who received the MTD had clinically meaningful responses.
Massive renal size is not a contraindication to a laparoscopic approach for bilateral native nephrectomies in autosomal dominant polycystic kidney disease ( ADPKD )
Wisenbaugh, Eric S., Tyson, Mark D. , Castle, Erik P., Humphreys, Mitchell R. , Andrews, Paul E.

BJU International | June 6, 2014 | Volume: 115 | Issue: 5 | Pages: 796-801

10.1111/bju.12821 | PMID 24903738 Get It

Objective To determine if massive renal size should be a contraindication for attempting a laparoscopic approach to bilateral native nephrectomies in patients with autosomal dominant polycystic kidney disease ( ADPKD ). Patients and Methods We retrospectively reviewed all laparoscopic bilateral nephrectomies performed for ADPKD at our institution from 1 J anuary 2000 to 31 D ecember 2012. We stratified patients by kidney weight (with or without at least one kidney weighing >2500 g) and compared perioperative data, complications, and status of kidney allografts. Additionally, the subset of patients with at least one kidney weighing >3500 g was compared with the rest of the cohort. Results We identified 68 patients; mean (range) individual kidney weight was 1984 (197–5042) g. In all, 24 patients had at least one kidney weighing >2500 g, yet patients in this group were not significantly different from the rest of the cohort for complications, estimated blood loss, transfusion rate, or duration of hospitalisation. For those who underwent simultaneous renal allotransplantation, native kidney size was not associated with graft outcomes. Additionally, of the six patients with at least one kidney weighing >3500 g, only one required a blood transfusion, and the group had no intraoperative or postoperative Clavien grade ≥3 complications. None of the cohort required conversion to open surgery. Conclusion Massive size of polycystic kidneys is not a contraindication to attempting a laparoscopic approach to bilateral nephrectomies in an experienced, high‐volume centre.
Three-Dimensional Spatiotemporal Features for Fast Content-Based Retrieval of Focal Liver Lesions
Chi, Yanling, Liu, Jimin , Venkatesh, Sudhakar K. , Brown, Michael S. , Roy, Sharmili , Venkatesh, Sudhakar K

IEEE Transactions on Biomedical Engineering | June 5, 2014 | Volume: 61 | Issue: 11 | Pages: 2768-2778

10.1109/tbme.2014.2329057 | PMID 24919041 Get It

Transvenous Stimulation of the Renal Sympathetic Nerves Increases Systemic Blood Pressure: A Potential New Treatment Option for Neurocardiogenic Syncope
Madhavan, Malini , Ebrille, Elisa , Mulpuru, Siva K. , Mikell, Susan B. , Johnson, Susan B., Suddendorf, Scott H., Ladewig, Dorothy J., Gilles, Emily J., Danielsen, Andrew J., Asirvatham, Samuel J. , DeSimone, Christopher V. , Asirvatham, Samuel J

Journal of Cardiovascular Electrophysiology | June 5, 2014 | Volume: 25 | Issue: 10 | Pages: 1115-1118

10.1111/jce.12466 | PMID 24902981 Get It

Renal Vein Stimulation Increases Blood PressureBackgroundNeurocardiogenic syncope (NCS) is a common and sometimes debilitating disorder, with no consistently effective treatment. NCS is due to a combination of bradycardia and vasodilation leading to syncope. Although pacemaker devices have been tried in treating the bradycardic aspect of NCS, no device‐based therapy exists to treat the coexistent vasodilation that occurs. The renal sympathetic innervation has been the target of denervation to treat hypertension. We hypothesized that stimulation of the renal sympathetic nerves can increase blood pressure and counteract vasodilation in NCS.Methods and ResultsHigh‐frequency stimulation (800–900 pps, 10 V, 30–200 seconds) was performed using a quadripolar catheter in the renal vein of 7 dogs and 1 baboon. A significant increase in blood pressure (BP; mean [SD] systolic BP 117 [±28] vs. 128 [±33], diastolic BP 75 [±19] vs. 87 [±29] mmHg) was noted during the stimulation, which returned to baseline after cessation of stimulation. The mean increase in systolic and diastolic BP was 13.0 (±3.3) (P = 0.006) and 10.2 (±4.6) (P = 0.08), respectively.ConclusionWe report the first ever study of feasibility and safety of high‐frequency electrical stimulation of the renal sympathetic innervation to increase BP in animal models. This has potential applications in the treatment of hypotensive states such as NCS.
The HELIOS Trial Protocol: A Phase III Study of Ibrutinib in Combination with Bendamustine and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia
Hallek, Michael , Österborg, Anders , Chanan‐Khan, Asher , Mahler, Michelle, Salman, Mariya, Wan, Ying , Sun, Steven , Zhuang, Sen Hong, Howes, Angela, Kay, Neil E.

Future Oncology | June 5, 2014 | Volume: 11 | Issue: 1 | Pages: 51-59

10.2217/fon.14.119 | PMID 24901734 Get It

Pyoderma gangrenosum: a possible cutaneous complication of levamisole‐tainted cocaine abuse
Keith, Phillip J., Joyce, Joel C. , Wilson, Barbara

International Journal of Dermatology | June 5, 2014 | Volume: 54 | Issue: 9 | Pages: 1075-1077

10.1111/ijd.12212 | PMID 24898775 Get It

Calcitonin gene‐related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria
Kay, A.B., Ying, S., Ardelean, E., Młynek, A., Kita, Hirohito , Maurer, Marcus , Ying, S., Clark, Patricia M. , Kita, H

Clinical & Experimental Allergy | June 5, 2014 | Volume: 44 | Issue: 8 | Pages: 1053-1060

10.1111/cea.12348 | PMID 24902612 Get It

Summary Background The mechanisms for producing weals in chronic spontaneous (idiopathic) urticaria (CSU) are incompletely understood. Leucocyte infiltration with vascular leakage and expression of the potent vasoactive agents' calcitonin gene‐related peptide ( CGRP ) and vascular endothelial growth factor ( VEGF ) are features of late‐phase allergic skin reactions, previously proposed as a model of CSU . Objective To measure CGRP and VEGF expression in lesional and non‐lesional skin from CSU patients and to compare results with a control group. Methods Eight paired biopsies (one from 4–8 h spontaneous weals and one from uninvolved skin) were taken from eight patients with CSU and nine control subjects and studied by immunohistochemistry and confocal microscopy. Results Lesional skin in CSU contained significantly more CGRP + and VEGF + cells than non‐lesional skin. No significant differences were observed in CGRP and VEGF expression between non‐lesional skin and controls. In lesional skin, VEGF and CGRP co‐localised to UEA‐1+ blood vessels. CGRP was also expressed by neutrophils and eosinophils and to a lesser extent by CD90 + fibroblasts, mast cells, CD 3 + and CD 68 + cells. CGRP and VEGF expression was not related to the duration of disease. Conclusion and Clinical Relevance Increased expression of CGRP and VEGF in lesional, but not uninvolved, skin indicates that these potent vasoactive agents may play a role in wealing and tissue oedema in CSU so representing novel targets in therapy.